FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Robert Schmouder

Research Profile

Chemicals & Drugs

Concepts & Ideas

Procedures

Disorders

Heart Rate

Physiology

Drug Interactions

Co-author Network

Publications

TOP 3
Craig Boulton; Olivier J David; Karin Meiser; Robert Schmouder
Pharmacodynamic effects of steady-state fingolimod on antibody response in healthy volunteers: a 4-week, randomized, placebo-controlled, parallel-group, multiple-dose study.
Olivier J David; Izaak den Daas; Corinne Emotte; Annamaria Jakab; Karin Meiser; Magdalena Ocwieja; Johan Wemer; Robert Schmouder
Pharmacokinetics of fingolimod (FTY720) and a combined oral contraceptive coadministered in healthy women: drug-drug interaction study results.
Kai Wu; Olivier J David; Francois Mercier; Robert Schmouder; Michael Looby
Population pharmacokinetics of fingolimod phosphate in healthy participants.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Robert Schmouder (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Craig Boulton; Olivier J David; Karin Meiser; Robert Schmouder
Pharmacodynamic effects of steady-state fingolimod on antibody response in healthy volunteers: a 4-week, randomized, placebo-controlled, parallel-group, multiple-dose study.
Journal of clinical pharmacology 2012;52(12):1879-90.
2012: Olivier J David; Izaak den Daas; Corinne Emotte; Annamaria Jakab; Karin Meiser; Magdalena Ocwieja; Johan Wemer; Robert Schmouder
Pharmacokinetics of fingolimod (FTY720) and a combined oral contraceptive coadministered in healthy women: drug-drug interaction study results.
International journal of clinical pharmacology and therapeutics 2012;50(8):540-4.
2012: Kai Wu; Olivier J David; Francois Mercier; Robert Schmouder; Michael Looby
Population pharmacokinetics of fingolimod phosphate in healthy participants.
Journal of clinical pharmacology 2012;52(7):1054-68.
2012: Robert Schmouder; Sam Hariry; Olivier J David
Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers.
European journal of clinical pharmacology 2012;68(4):355-62.
2010: Volker Brinkmann; Andreas Billich; Thomas Baumruker; Peter Heining; Robert Schmouder; Gordon Francis; Shreeram Aradhye; Pascale Burtin
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.
Nature reviews. Drug discovery 2010;9(11):883-97.
2010: Helio Tedesco Silva; Claudia Rosso Felipe; Sung I Park; Paula G Pinheiro Machado; Riberto Garcia; Alan Slade; Robert Schmouder; Jose O Medina-Pestana
Randomized crossover study to assess the inter- and intrasubject variability of morning mycophenolic acid concentrations from enteric-coated mycophenolate sodium and mycophenolate mofetil in stable renal transplant recipients.
Clinical transplantation 2010;24(4):E116-23.
2010: Joseph V Bonventre; Vishal S Vaidya; Robert Schmouder; Peter Feig; Frank Dieterle
Next-generation biomarkers for detecting kidney toxicity.
Nature biotechnology 2010;28(5):436-40.
2008: John M Kovarik; Gilles-Jacques Riviere; Daniel Neddermann; Steve Maton; Thomas L Hunt; Robert Schmouder
A mechanistic study to assess whether isoproterenol can reverse the negative chronotropic effect of fingolimod.
Journal of clinical pharmacology 2008;48(3):303-10.
2007: Klemens Budde; Helio Tedesco Silva; Jose Medina Pestana; Petra Glander; Hans-Hellmut Neumayer; Claudia Rosso Felipe; Paula Pinheiro Machado; Romain Sechaud; Robert Schmouder
Enteric-coated mycophenolate sodium provides higher mycophenolic acid predose levels compared with mycophenolate mofetil: implications for therapeutic drug monitoring.
Therapeutic drug monitoring 2007;29(3):381-4.
2007: John M Kovarik; Stefan Hartmann; Michael Bartlett; Gilles-Jacques Riviere; Daniel Neddermann; Yibin Wang; Andreas Port; Robert Schmouder
Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects.
Biopharmaceutics & drug disposition 2007;28(2):97-104.
2007: John M Kovarik; Alan Slade; B Voss; Heinz Schmidli; Gilles-Jacques Riviere; F Picard; Y Sugita; R Kawai; D Mee-Lee; Robert Schmouder
Ethnic sensitivity study of fingolimod in white and Asian subjects.
International journal of clinical pharmacology and therapeutics 2007;45(2):98-109.
2006: John M Kovarik; Doris Beyer; Robert Schmouder
Everolimus drug interactions: application of a classification system for clinical decision making.
Biopharmaceutics & drug disposition 2006;27(9):421-6.
2006: W Arns; M Gies; Les Choi; W Zhu; P Cooper; Ching-Ming Yeh; P Prasad; P Graf; Robert Schmouder
Absorption characteristics of EC-MPS--an enteric-coated formulation of mycophenolic sodium.
International journal of clinical pharmacology and therapeutics 2006;44(8):375-85.
2006: Jasper J Haringman; Danielle M Gerlag; Tom J M Smeets; Dominique Baeten; Filip van den Bosch; Barry Bresnihan; Ferdinand C Breedveld; Huibert J Dinant; Francois Legay; Hermann Gram; Pius Loetscher; Robert Schmouder; Thasia Woodworth; Paul P Tak
A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis.
Arthritis and rheumatism 2006;54(8):2387-92.
2006: Robert Schmouder; Denise Serra; Yibin Wang; John M Kovarik; John DiMarco; Thomas L Hunt; Marie-Claude Bastien
FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects.
Journal of clinical pharmacology 2006;46(8):895-904.
2006: John M Kovarik; Adele Noe; Yibin Wang; Irene Mueller; Gilberto DeNucci; Robert Schmouder
Differentiation of innovator versus generic cyclosporine via a drug interaction on sirolimus.
European journal of clinical pharmacology 2006;62(5):361-6.
2006: John M Kovarik; Robert Schmouder; Stefan Hartmann; Gilles-Jacques Riviere; Franck Picard; Brigitta Voss; Markus Weiss; Frank Wagner; Hartmut H-J Schmidt
Fingolimod (FTY720) in severe hepatic impairment: pharmacokinetics and relationship to markers of liver function.
Journal of clinical pharmacology 2006;46(2):149-56.
2005: Robert Ettenger; Sharon Bartosh; Les Choi; Wei Zhu; Werner Niederberger; Joelle Campestrini; Marie-Claude Bastien; Robert Schmouder
Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients.
Pediatric transplantation 2005;9(6):780-7.
2005: Andrej Skerjanec; Helio Tedesco; Hans-Hellmut Neumayer; Edward Cole; Klemens Budde; Chyi-Hung Hsu; Robert Schmouder
FTY720, a novel immunomodulator in de novo kidney transplant patients: pharmacokinetics and exposure-response relationship.
Journal of clinical pharmacology 2005;45(11):1268-78.
2005: John M Kovarik; D Beyer; Marie-Noelle Bizot; Q Jiang; M J Allison; Robert Schmouder
Pharmacokinetic interaction between verapamil and everolimus in healthy subjects.
British journal of clinical pharmacology 2005;60(4):434-7.
2005: Bruce Kaplan; Herwig-Ulf Meier-Kriesche; Paula Minnick; Marie-Claude Bastien; Romain Sechaud; Ching-Ming Yeh; Sebastien Balez; Franck Picard; Robert Schmouder
Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co-administered enteric-coated mycophenolate sodium.
Clinical transplantation 2005;19(4):551-8.
2005: Sung Park; Claudia Rosso Felipe; P G P Machado; Riberto Garcia; Andrej Skerjanec; Robert Schmouder; H Tedesco-Silva Jr; José O Medina Pestana
Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients.
Brazilian journal of medical and biological research = Revista brasileira de pesquisas médicas e biológicas / Sociedade Brasileira de Biofísica ... [et al.] 2005;38(5):683-94.
2005: John M Kovarik; D Beyer; Marie-Noelle Bizot; Q Jiang; M Shenouda; Robert Schmouder
Blood concentrations of everolimus are markedly increased by ketoconazole.
Journal of clinical pharmacology 2005;45(5):514-8.
2005: John M Kovarik; Robert Schmouder; D Serra; Y Wang; H Wiegand; Stacy C Dilzer; Kenneth C Lasseter
FTY720 pharmacokinetics in mild to moderate hepatic impairment.
Journal of clinical pharmacology 2005;45(4):446-52.
2005: Wolfgang Arns; Stephan Breuer; Somesh Choudhury; Guy Taccard; James Lee; Vera Binder; Jürgen Roettele; Robert Schmouder
Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil.
Clinical transplantation 2005;19(2):199-206.
2005: Helio Tedesco Silva; Marie-Claude Bastien; Les Choi; Claudia Rosso Felipe; Joelle Campestrini; F Picard; Robert Schmouder
Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil.
Transplantation proceedings 2005;37(2):852-5.
2005: John M Kovarik; D Beyer; Marie-Noelle Bizot; Q Jiang; M Shenouda; Robert Schmouder
Effect of multiple-dose erythromycin on everolimus pharmacokinetics.
European journal of clinical pharmacology 2005;61(1):35-8.
2004: John M Kovarik; Robert Schmouder; Alan Slade
Overview of FTY720 clinical pharmacokinetics and pharmacology.
Therapeutic drug monitoring 2004;26(6):585-7.
2004: John M Kovarik; Robert Schmouder; Denise Barilla; Monika Büche; Marisel Rouilly; Stephane Berthier; Yibin Wang; Claudia Van Saders; Thomas Mayer; Alice B Gottlieb
FTY720 and cyclosporine: evaluation for a pharmacokinetic interaction.
The Annals of pharmacotherapy 2004;38(7-8):1153-8.
2004: John M Kovarik; Robert Schmouder; Denise Barilla; Gilles-Jacques Riviere; Yibin Wang; Thomas Hunt
Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects.
Journal of clinical pharmacology 2004;44(5):532-7.
2004: John M Kovarik; Robert Schmouder; Denise Barilla; Yibin Wang; Gerolf Kraus
Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects.
British journal of clinical pharmacology 2004;57(5):586-91.
2003: Barry D Kahan; Janet L Karlix; Ronald M Ferguson; Alan B Leichtman; Shamkant Mulgaonkar; Thomas A Gonwa; Andrej Skerjanec; Robert Schmouder; Lawrence Chodoff
Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study.
Transplantation 2003;76(7):1079-84.
2002: John M Kovarik; Denise Barilla; Louis McMahon; Yibin Wang; James Kisicki; Robert Schmouder
Administration diluents differentiate Neoral from a generic cyclosporine oral solution.
Clinical transplantation 2002;16(4):306-9.
2002: Klemens Budde; Robert Schmouder; Reinhard Brunkhorst; Björn Nashan; Peter W Lücker; Thomas Mayer; Somesh Choudhury; Andrej Skerjanec; Gerolf Kraus; Hans-Hellmut Neumayer
First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients.
Journal of the American Society of Nephrology : JASN 2002;13(4):1073-83.
1999: Akinlolu O Ojo; T C Govaerts; Robert Schmouder; Alan B Leichtman; Sean F Leavey; Robert A Wolfe; Philip J Held; Friedrich K Port; Lawrence Y Agodoa
Renal transplantation in end-stage sickle cell nephropathy.
Transplantation 1999;67(2):291-5.
1998: Akinlolu O Ojo; Robert A Wolfe; Lawrence Y Agodoa; Philip J Held; Friedrich K Port; Sean F Leavey; S E Callard; David M Dickinson; Robert Schmouder; Alan B Leichtman
Prognosis after primary renal transplant failure and the beneficial effects of repeat transplantation: multivariate analyses from the United States Renal Data System.
Transplantation 1998;66(12):1651-9.
1997: Akinlolu O Ojo; Robert A Wolfe; Philip J Held; Friedrich K Port; Robert Schmouder
Delayed graft function: risk factors and implications for renal allograft survival.
Transplantation 1997;63(7):968-74.
1995: Robert Schmouder; R M Streiter; A Walz; Steven Kunkel
Epithelial-derived neutrophil-activating factor-78 production in human renal tubule epithelial cells and in renal allograft rejection.
Transplantation 1995;59(1):118-24.
1995: Robert Schmouder; Steven Kunkel
The cytokine response in renal allograft rejection.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 1995;10 Suppl 1():36-43.
1994: D Kim Turgeon; Alan B Leichtman; D S Blake; Robert Schmouder; Kenneth S Lown; Thomas M Annesley; Paul B Watkins
Prediction of interpatient and intrapatient variation in OG 37-325 dosing requirements by the erythromycin breath test. A prospective study in renal transplant recipients.
Transplantation 1994;57(12):1736-41.
1993: Robert Schmouder; Robert M Strieter; Steven Kunkel
Interferon-gamma regulation of human renal cortical epithelial cell-derived monocyte chemotactic peptide-1.
Kidney international 1993;44(1):43-9.
1992: Robert Schmouder; Robert M Strieter; Roger C Wiggins; Stephen W Chensue; Steven Kunkel
In vitro and in vivo interleukin-8 production in human renal cortical epithelia.
Kidney international 1992;41(1):191-8.
1990: Alan B Weder; Robert Schmouder; B A Torretti
Platelet volume responses to cytoplasmic acidification in essential hypertension.
Journal of hypertension 1990;8(12):1137-42.
1989: Robert Schmouder; Alan B Weder
Platelet sodium-proton exchange is increased in essential hypertension.
Journal of hypertension 1989;7(4):325-30.
1988: Brent M Egan; Robert Schmouder
The importance of hemodynamic considerations in essential hypertension.
American heart journal 1988;116(2 Pt 2):594-9.